FrancophonIA/ELRC3.0 huggingface dataset:
English: As with all cephalosporins, the action of cefovecin results from the inhibition of bacterial cell wall synthesis; cefovecin has bactericidal activity.
Croatian: Kao i svi cefalosporini, djelovanje cefovecina rezultat je inhibicije sinteze stanične stjenke bakterija; cefovecin ima baktericidno djelovanje.
English: Special precautions to be taken by the person administering the veterinary medicinal product to animals
Croatian: Posebne mjere opreza koje mora poduzeti osoba koja primjenjuje veterinarsko-medicinski proizvod na životinjama
English: TARGET SPECIES Dogs and cats.
Croatian: CILJNE VRSTA ŽIVOTINJA Psi i mačke.
English: Resistance to cephalosporins results from enzymatic inactivation (β-lactamase production) or from other mechanisms.
Croatian: Otpornost na cefalosporine uzrokovana je enzimskom inaktivacijom (proizvodnja β-laktamaze) ili drugim mehanizmima.
English: Cross resistance with other cephalosporins and other beta-lactam antibacterial agents can be observed.
Croatian: Može se uočiti križna otpornost s drugim cefalosporinima i drugim beta-laktamskim antibakterijskim sredstvima.
English: Bacterial Pathogen Origin
Croatian: Bakterijski patogen Izvor
English: PACKAGE SIZE 10 ml (after reconstitution) 4 ml (after reconstitution)
Croatian: VELIČINA PAKOVANJA 10 ml (nakon rekonstitucije) 4 ml (nakon rekonstitucije)
English: The percentage of cefovecin resistant isolates in E. coli, Prevotella oralis, Bacteroides spp.
Croatian: Postotak izolata otpornih na cefovecin u E. coli, Prevotella oralis, Bacteroides spp.
English: 5.2 Pharmacokinetic particulars
Croatian: 5.2 Farmakokinetički podaci
English: QUANTITY OF THE ACTIVE SUBSTANCE(S) Each vial contains 852 mg cefovecin.
Croatian: KOLIČINA DJELATNE(IH) TVARI Svaka bočica sadrži 852 mg cefovecina.
English: 4.9 Amounts to be administered and administration route
Croatian: 4.9 Količine koje se primjenjuju i put primjene
English: Do not use in small herbivores (including guinea pigs and rabbits).
Croatian: Na primjenjivati na malim biljojedima (uključujući zamorčiće i kuniće).
English: Resistance to cephalosporins results from enzymatic inactivation (β-lactamase production), from reduced permeability by porin mutations or change in efflux, or by selection of low-affinity penicillin-binding proteins.
Croatian: Otpornost na cefalosporine uzrokovana je enzimskom inaktivacijom (proizvodnja β-laktamaze), od smanjene propusnosti mutacijama porina ili promjene u efluksu, ili selekcijom proteina sa niskim afinitetom vezanja na penicilin.
English: Cefovecin has unique pharmacokinetic properties with extremely long elimination half-lives in both dogs and cats.
Croatian: Cefovecin ima jedinstvena farmakokinetička svojstva s ekstremno dugačkim poluživotom eliminacije u mačaka i u pasa.
English: SPECIAL STORAGE PRECAUTIONS Keep out of the sight and reach of children.
Croatian: 11. POSEBNE MJERE PRI ČUVANJU Čuvati izvan dosega i pogleda djece.
English: Urinary tract infections in dogs and cats: A single subcutaneous injection.
Croatian: Infekcije urinarnog trakta u pasa i mačaka: Pojedinačna subkutana injekcija.
English: Reconstitution yields either 4 ml or 10 ml of solution for injection respectively.
Croatian: Rekonstitucijom se dobiva 4 ml ili 10 ml otopine za injekciju.
English: On very rare occasions gastrointestinal signs, including emesis and/or diarrhoea, have been observed.
Croatian: U vrlo rijetkim slučajevima uočeni su gastrointestinalni znakovi, uključujući povraćanje i/ili proljev.
English: THE WORDS “FOR ANIMAL TREATMENT ONLY” For animal treatment only.
Croatian: RIJEČI “SAMO ZA PRIMJENU NA ŽIVOTINJAMA” Samo za primjenu na životinjama.
English: It is prudent to reserve third generation cephalosporins for the treatment of clinical conditions, which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials or first generation cephalosporins.
Croatian: Razborito je sačuvati cefalosporine treće generacije za liječenje kliničkih stanja sa slabom reakcijom, ili očekivanom slabom reakcijom, na ostale klase antimikrobnih sredstava ili cefalosporine prve generacije.
English: Shelf-life after reconstitution according to directions: 28 days.
Croatian: Rok valjanosti nakon rekonstitucije prema uputi: 28 dana.
English: In very rare cases neurological signs and injection site reactions have been reported after the use of the product.
Croatian: U vrlo rijetkim slučajevima nakon primjene proizvoda prijavljeni su neurološki znakovi i reakcije na mjestu ubrizgavanja.
English: After reconstitution, use within 28 days.
Croatian: Upotrijebiti u roku od 28 dana nakon rekonstitucije.
English: Pharmacotherapeutic group: Antibacterials for systemic use (cephalosporins).
Croatian: Farmakoterapijska grupa: antibakterijska sredstva za sustavnu primjenu (cefalosporini).
English: Do not use in cases of hypersensitivity to cephalosporin or penicillin antibiotics.
Croatian: Ne primjenjivati u slučajevima preosjetljivosti na cefalosporinske ili penicilinske antibiotike.
English: Peak concentrations in tissue cage fluid of 31.9 μg/ml were measured 2 days after administration.
Croatian: Najviše vrijednosti koncentracija u tkivnoj tekućini od 31,9 µg/ml izmjerene su 2 dana nakon primjene.
English: Special precautions for use in animals:
Croatian: Posebne mjere opreza prilikom primjene na životinjama:
English: Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact.
Croatian: Penicilini i cefalosporini mogu uzrokovati preosjetljivost (alergiju) nakon ubrizgavanja, udisanja, gutanja ili kontakta s kožom.
English: QUANTITY OF THE ACTIVE SUBSTANCE(S) 340 mg cefovecin
Croatian: KOLIČINA DJELATNE(IH) TVARI 340 mg cefovecina
English: Pyoderma is often secondary to an underlying disease.
Croatian: Pioderma se često pojavljuje kao sekundarna bolest, uz neku drugu bolest.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Croatian: Učestalost nuspojava je određena sukladno sljedećim pravilima: - vrlo česte (više od 1 na 10 tretiranih životinja pokazuju nuspojavu(e) - česte (više od 1 ali manje od 10 životinja na 100 tretiranih životinja) - manje česte (više od 1 ali manje od 10 životinja na 1.000 tretiranih životinja) - rijetke (više od 1 ali manje od 10 životinja na 10.000 tretiranih životinja) - vrlo rijetke (manje od 1 životinje na 10.000 tretiranih životinja, uključujući izolirane slučajeve).
English: MARKETING AUTHORISATION NUMBER(S) EU/2/06/059/001 (23 ml)
Croatian: 16. BROJEVI ODOBRENJA ZA STAVLJANJE U PROMET EU/2/06/059/001 (23 ml)
English: 6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Croatian: 6.6 Posebne mjere opreza prilikom odlaganja neupotrebljenog veterinarsko-medicinskog proizvoda ili otpadnih materijala dobivenih primjenom tih proizvoda
English: The safety of Convenia has not been assessed in animals suffering from severe renal dysfunction.
Croatian: Neškodljivost Convenije nije ispitana u životinja koje pate od teškog poremećaja bubrežne funkcije.
English: If an allergic reaction occurs, no further administrations of cefovecin should be administered and appropriate therapy for beta-lactam hypersensitivity should be instituted.
Croatian: Ako dođe do alergijske reakcije, cefovecin se više ne bi smio primjenjivati, a trebalo bi uvesti odgovarajuću terapiju za preosjetljivost na beta-laktamske antibiotike.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated ) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Croatian: Učestalost nuspojava je određena sukladno sljedećim pravilima: - vrlo česte (više od 1 na 10 tretiranih životinjapokazuju nuspojavu(e)) - česte (više od 1 ali manje od 10 životinja na 100 tretiranih životinja) - manje česte (više od 1 ali manje od 10 životinja na 1.000 tretiranih životinja) - rijetke (više od 1 ali manje od 10 životinja na 10.000 tretiranih životinja) - vrlo rijetke (manje od 1 životinje na 10.000 tretiranih životinja, uključujući izolirane slučajeve).
English: Dog Cat Pasteurella multocida Dog Cat
Croatian: Pasteurella multocida pas mačka
English: In-vitro activity against these pathogens as well as against other skin and urinary tract pathogens collected during a European (Denmark, France, Germany, Italy and United Kingdom) MIC survey (1999 - 2000)
Croatian: In-vitro djelovanje na te patogene, kao i na ostale patogene kože i urinarnog trakta, prikupljene tijekom europskog ispitivanja MIC-a (u Danskoj, Francuskoj, Italiji, Njemačkoj i Ujedinjenom Kraljevstvu, 1999. - 2000.) i tijekom terenskih studija kliničke djelotvornosti i neškodljivosti u Europi (u Francuskoj, Njemačkoj, Španjolskoj i Ujedinjenom Kraljevstvu, 2001. - 2003.) navedeni su u nastavku.
English: Powder and solvent for solution for injection.
Croatian: Prašak i otapalo za otopinu za injekciju.
English: In dogs, when cefovecin was administered as a single subcutaneous dose of 8 mg/kg bodyweight, absorption was rapid and extensive; peak plasma concentration at 6 hours was 120 µg/ml and bioavailability approximately 99 %.
Croatian: Kada je cefovecin primijenjen kao pojedinačna subkutana doza od 8 mg/kg tjelesne težine u pasa, apsorpcija je bila rapidna i ekstenzivna; najviša koncentracija u plazmi nakon 6 sati bila je 120 µg/ml, a bioraspoloživost približno 99%.
English: Cat
Croatian: mačka
English: Caution should be exercised in patients that have previously shown hypersensitivity reactions to cefovecin, other cephalosporins, penicillins, or other drugs.
Croatian: Posebne mjere predostrožnosti treba poduzeti u pacijenata koji su prethodno već imali hipersenzitivne reakcije na cefovecin, druge cefalosporine, peniciline i ostale lijekove.
English: Manufacturer responsible for batch release: Haupt Pharma Latina S.r.l.
Croatian: PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE U PROMET Naziv i adresa proizvođača odgovornog za puštanje serije u promet Haupt Pharma Latina S.r.l.
English: Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures, including oxygen, intravenous fluids, intravenous antihistamine, corticosteroids, and airway management, as clinically indicated.
Croatian: Ozbiljne, akutne hipersenzitivne reakcije mogu zahtijevati liječenje epinefrinom i druge hitne mjere, uključujući kisik, intravenske tekućine, intravenske antihistaminike, kortikosteroide i uspostavljanje dišnog puta, prema kliničkim indikacijama.
English: For the treatment of urinary tract infections associated with Escherichia coli and/or Proteus spp.
Croatian: Za liječenje infekcija urinarnog trakta vezanih uz Escherichiju coli i/ili Proteus spp.
English: At ten and fourteen days after administration, urine concentrations were 1.3 µg/ml and 0.7 µg/ml, respectively.
Croatian: Deseti i četrnaesti dan nakon primjene koncentracije u urinu bile su 1,3 µg/ml, odnosno 0,7 µg/ml.
English: MANUFACTURER'S BATCH NUMBER Lot: {number}
Croatian: 17. BROJ PROIZVODNE SERIJE PROIZVOĐAČA
English: MARKETING AUTHORISATION NUMBER(S) EU/2/06/059/001 (23 ml vial) EU/2/06/059/002 (5 ml vial)
Croatian: BROJ(EVI) ODOBRENJA ZA STAVLJANJE U PROMET EU/2/06/059/001 (bočica od 23 ml) EU/2/06/059/002 (bočica od 5 ml)
English: When applying a proposed microbiological breakpoint of I ≤ 4 µg/ml, cefovecin resistance in S. pseudintermedius and beta-haemolytic Streptococci isolates was less than 0.02 % and 3.4 % in Prevotella intermedia isolates.
Croatian: Kada je primijenjena predložena mikrobiološka granična vrijednost od I ≤ 4 ≤µg /ml, otpornost na cefovecin u izolatima S. pseudintermedius i beta-hemolitičkih streptokoka bila je manja od 0,02%, odnosno 3,4% u izolatima
English: PHARMACEUTICAL FORM Powder and solvent for solution for injection.
Croatian: OBLIK Prašak i otapalo za otopinu za injekciju.
English: When applying a proposed microbiological breakpoint of S ≤ 2 µg/ml, no resistance to cefovecin was detected in Pasteurella multocida, Fusobacterium spp.
Croatian: Kada je primijenjena predložena mikrobiološka granična vrijednost od S ≤ 2 ≤µg /ml, nikakva otpornost na cefovecin nije otkrivena u terenskim izolatima bakterija Pasteurella multocida, Fusobacterium spp. i Porphyromonas spp.
English: Skin and soft tissue infections in dogs:
Croatian: Infekcije kože i mekih tkiva u pasa:
English: Dog 29 ≤0.008
Croatian: mačka 23 ≤0,06
English: CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 10 ml (after reconstitution)
Croatian: SADRŽAJ PO TEŽINI, VOLUMENU ILI BROJ DOZA 10 ml (nakon rekonstitucije)
English: 13 mg/ml benzyl alcohol 4.45 ml water for injections
Croatian: 13 mg/ml benzilnog alkohola 4,45 ml vode za injekciju
English: CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 4 ml (after reconstitution)
Croatian: SADRŽAJ PO TEŽINI, VOLUMENU ILI BROJ DOZA 4 ml (nakon rekonstitucije)
English: Coagulase positive Staphylococcus spp.3, 4
Croatian: Koagulaza-pozitivni Staphylococcus spp.3, 4
English: Discard date:
Croatian: Datum odbacivanja:
English: QUANTITY OF OTHER SUBSTANCES 13 mg/ml benzyl alcohol in water for injections.
Croatian: KOLIČINA OSTALIH TVARI 13 mg/ml benzilnog alkohola u vodi za injekcije.
English: Coagulase negative Staphylococcus spp.4
Croatian: Koagulaza-negativni Staphylococcus spp.4
English: Pseudomonas spp., Enterococcus spp., and Bordetella bronchiseptica isolates are inherently resistant to cefovecin.
Croatian: Izolati bakterija Pseudomonas spp., Enterococcus spp., i Bordetella bronchiseptica inherentno su rezistentni na cefovecin.
English: Disposal: read package leaflet.
Croatian: Odlaganje: pročitati uputu o VMP.
English: 852 mg cefovecin (as sodium salt) Excipients:
Croatian: 852 mg cefovecina (kao natrijeve soli) Pomoćne tvari:
English: To reconstitute, withdraw the required volume of the supplied diluent from its vial (for 23 ml vial containing 852 mg of lyophilised powder reconstitute using 10 ml of diluent, or for 5 ml vial containing 340 mg of lyophilised powder reconstitute using 4 ml of diluent) and add to the vial containing the lyophilised powder.
Croatian: Za rekonstituciju izvucite potrebnu količinu otapala iz bočice (za 23 ml bočicu koja sadrži 852 mg liofiliziranog praška rekonstituirati koristeći 10 ml otapala ili za bočicu od 5 ml koja sadrži 340 mg liofiliziranog praška rekonstituirati koristeći 4 ml otapala) i dodajte ga u bočicu s liofiliziranim praškom.
English: Pack size: 1 vial of powder and 1 vial of diluent.
Croatian: Veličina pakovanja: 1 bočica praška i 1 bočica otapala.
English: DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION Dogs and cats: 8 mg cefovecin/kg body weight (1 ml/10 kg body weight).
Croatian: DOZIRANJE ZA SVAKU CILJNU VRSTU ŽIVOTINJA, NAČIN I PUT(EVI) PRIMJENE Psi i mačke: 8 mg cefovecina/kg tjelesne težine (1 ml/10 kg tjelesne težine).
English: Dog 272 ≤0.008
Croatian: mačka 24 ≤0,06
English: For the treatment of urinary tract infections associated with Escherichia coli.
Croatian: Za liječenje infekcija urinarnog trakta vezanih uz Escherichiju coli.
English: SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
Croatian: 13. POSEBNE MJERE OPREZA PRILIKOM ODLAGANJA NEUPOTREBLJENOG PROIZVODA ILI OTPADNIH MATERIJALA, AKO IH IMA
English: Escherichia coli
Croatian: Escherichia coli pas mačka
English: Fourteen days after administration the mean cefovecin concentration in plasma was 18 µg/ml.
Croatian: Četrnaest dana nakon primjene srednja koncentracija cefovecina u plazmi bila je 18 µg/ml.
English: The product is available in a single pack of either 5 ml or 23 ml, composed of a vial containing the freezedried powder, and a second vial containing the diluent.
Croatian: Proizvod je dostupan u jediničnom pakovanju od 5 ml ili 23 ml sastavljenom od bočice s liofiliziranim praškom i druge bočice s otapalom.
English: Repeated dosing (eight administrations) in 14-day intervals at five times the recommended dose was tolerated well in young dogs.
Croatian: Mladi psi dobro su podnijeli ponovljeno doziranje (osam primjena) u intervalima od 14 dana u dozi peterostruko većoj od preporučene.
English: Special precautions for use in animals
Croatian: Posebne mjere opreza prilikom primjene na životinjama
English: Repeated dosing (eight administrations) in 14-day intervals at five times the recommended dose was tolerated well in young cats.
Croatian: Mlade mačke dobro su podnijele ponovljeno doziranje (osam primjena) u intervalima od 14 dana u dozi peterostruko većoj od preporučene.
English: WITHDRAWAL PERIOD(S) Not applicable.
Croatian: KARENCIJA(E) Nije primjenjivo.
English: Each 5 ml vial of lyophilised powder contains:
Croatian: Svaka bočica liofiliziranog praška od 5 ml sadrži:
English: CONTENTS BY WEIGHT, BY VOLUME OR NUMBER OF DOSES
Croatian: SADRŽAJ PO TEŽINI, VOLUMENU IIL BROJU DOZA
English: When reconstituted according to label instructions, the solution for injection contains: 80.0 mg/ml cefovecin (as sodium salt)
Croatian: SASTAV DJELATNIH TVARI Kada se rekonstituira prema uputama, otopina za injekciju sadrži: 80,0 mg/ml cefovecina (kao natrijeve soli)
English: A single subcutaneous injection of 8 mg/kg bodyweight (1 ml per 10 kg bodyweight).
Croatian: Pojedinačna subkutana injekcija od 8 mg/kg tjelesne težine (1 ml na 10 kg tjelesne težine).
English: EXPIRY DATE EXP:
Croatian: ROK VALJANOSTI EXP:
English: Fourteen days after administration, the mean cefovecin concentration in plasma was 5.6 μg/ml.
Croatian: Četrnaest dana nakon primjene srednja koncentracija cefovecina u plazmi bila je 5,6 µg/ml.
English: Skin and soft tissue abscesses and wounds in cats:
Croatian: Apscesi i rane na koži i mekom tkivu u mačaka:
English: Do not use this veterinary medicinal product after the expiry date which is stated on the carton.
Croatian: Ne koristiti poslije isteka roka valjanosti naznačenog na kutiji.
English: Citric acid
Croatian: Benzilni alkohol Natrijev citrat Limunska kiselina
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each 23 ml vial of lyophilised powder contains: Active substance:
Croatian: KVALITATIVNI I KVANTITATIVNI SASTAV Svaka bočica liofiliziranog praška od 23 ml sadrži:
English: For the treatment of skin and soft tissue infections including pyoderma, wounds and abscesses associated with Staphylococcus pseudintermedius, β-haemolytic Streptococci, Escherichia coli and/or Pasteurella multocida.
Croatian: Za liječenje infekcija kože i mekog tkiva uključujući piodermu, rane i apscese vezane uz Staphylococcus pseudintermedius, β-hemolitičke streptokoke, Escherichiju coli i/ili Pasteurellu multocidu.
English: 4.5 Special precautions for use
Croatian: 4.5 Posebne mjere opreza prilikom primjene
English: At fourteen days after administration, urine concentrations were 2.9 μg/ml.
Croatian: Četrnaesti dan nakon primjene koncentracije u urinu bile su 2,9 µg/ml.
English: 6.4 Special precautions for storage
Croatian: 6.4 Posebne mjere pri čuvanju
English: Dog Cat
Croatian: pas mačka
English: Dog Cat4
Croatian: mačka4
English: EXPIRY DATE EXP: {mm/yyyy}
Croatian: ROK VALJANOSTI EXP: {mm/gggg}
English: Type I glass vial of either 10 ml or 19 ml with chlorobutyl rubber stopper sealed with an aluminium flipoff seal.
Croatian: I od 10 ml ili 19 ml s čepom od klorobutilne gume zatvorena aluminijskom kapicom sa poklopcem za otkidanje.
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Diluent for Convenia
Croatian: NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
English: Staphylococcus pseudintermedius
Croatian: Staphylococcus pseudintermedius pas mačka β hemolitički
English: In addition, cefovecin exhibits in-vitro activity against Escherichia coli which is associated with canine and feline urinary tract infections.
Croatian: Osim toga, cefovecin pokazuje in-vitro djelovanje na Escherichiju coli koja je vezana uz infekcije urinarnog trakta pasa i mačaka.
English: Active substance:
Croatian: Djelatna tvar:
English: Severe infections of the gingival and periodontal tissues in dogs: A single subcutaneous injection of 8 mg/kg bodyweight (1 ml per 10 kg bodyweight).
Croatian: Teške infekcije gingivalnih i periodontalnih tkiva u pasa: Pojedinačna subkutana injekcija od 8 mg/kg tjelesne težine (1 ml na 10 kg tjelesne težine).
English: Dosing Table: Animal Weight (Dogs and Cats) Volume to be Administered 2.5 kg
Croatian: Tablica za doziranje Težina životinje (psi i mačke)
English: Dog4 Cat
Croatian: pas mačka4
English: Cefovecin exhibits in-vitro activity against Staphylococcus pseudintermedius and Pasteurella multocida which are associated with canine and feline skin infections.
Croatian: Cefovecin pokazuje in-vitro djelovanje na bakterije Staphylococcus pseudintermedius i Pasteurella multocida koje su vezane uz kožne infekcije pasa i mačaka.
English: MARKETING AUTHORISATION HOLDER
Croatian: Nositelj odobrenja za stavljanje u promet:
English: Cefovecin exhibits in vitro activity against Staphylococcus pseudintermedius and Pasteurella multocida which are associated with canine and feline skin infections.
Croatian: Cefovecin demonstrira in vitro djelovanje na bakterije Staphylococcus pseudintermedius i Pasteurella multocida koje su vezane uz kožne infekcije pasa i mačaka.
English: MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Croatian: PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE U PROMET
English: Urinary tract infections in dogs and cats: A single subcutaneous injection of 8 mg/kg bodyweight (1 ml per 10 kg bodyweight).
Croatian: Infekcije urinarnog trakta u pasa i mačaka: Pojedinačna subkutana injekcija od 8 mg/kg tjelesne težine (1 ml na 10 kg tjelesne težine).
English: Haupt Pharma Latina S.r.l.
Croatian: Haupt Pharma Latina S.r.l. S.S. 156 Km 47,600
English: As adjunctive treatment to mechanical or surgical periodontal therapy in the treatment of severe infections of the gingiva and periodontal tissues associated with Porphyromonas spp.
Croatian: Kao pomoćna terapija uz mehaničku ili kiruršku periodontalnu terapiju u liječenju teških infekcija gingive i periodontalnih tkiva vezanih uz Porphyromonas spp. i Prevotellu spp. (Također vidi odjeljak 4.5 “Posebne mjere opreza prilikom primjene”.)
English: ROUTE(S) OF ADMINISTRATION Read the package leaflet before use.
Croatian: PUT(EVI) PRIMJENE Pročitati uputu o VMP prije primjene.
English: 13 mg/ml benzyl alcohol
Croatian: 12,3 mg/ml benzilnog alkohola
English: Active substance: 340 mg cefovecin (as sodium salt)
Croatian: 340 mg cefovecina (kao natrijeve soli) Pomoćne tvari:
English: 19.17 mg methyl parahydroxybenzoate (E218) 2.13 mg propyl parahydroxybenzoate (E216) Each 19 ml vial of diluent contains:
Croatian: 19,17 mg metil-parahidroksibenzoata (E218) 2,13 mg propil-parahidroksibenzoata (E216) Svaka bočica otapala od 19 ml sadrži: Pomoćne tvari:
English: Dosing Table
Croatian: Tablica za doziranje
English: field isolates.
Croatian: Broj izolata
English: Powder: Type I glass vial of either 5 ml or 23 ml with butyl rubber stopper sealed with an aluminium flip-off seal.
Croatian: I od 5 ml ili 23 ml s čepom od butilne gume zatvorena aluminijskom kapicom sa poklopcem za otkidanje.
English: Excipients:
Croatian: Prašak:
English: The percentage of cefovecin resistant isolates in coagulase negative Staphylococcus spp.
Croatian: Postotak izolata otpornih na cefovecin u koagulaza-negativnim Staphylococcus spp. (npr. S. xylosus, S. schleiferi, S. epidermidis) iznosi 9,5%.